Prakasini Satapathy, Shilpa Gaidhane, Gaurav Sanghvi, Subbulakshmi Ganesan, Swati Mishra, Krishnakumar Samikan, Ashutosh Jena, Mahendra Singh, Sanjit Sah, Shubham Kumar, Khang Wen Goh, Muhammed Shabil
Objectives: This study aims to assess the burden of prostate cancer (PCa) in Central and Eastern Europe (CEE) by analyzing historical trends, evaluating the current burden, and forecasting future trends. Methods: This study uses data from the Global Burden of Disease (GBD) study spanning 1990–2021 to analyze PCa trends in CEE. We assessed age-standardized rates (ASRs) of PCa to identify trend changes through joinpoint regression analysis, explored regional disparities using QGIS software, and made projections for 2031 using the ARIMA model. Results: Eastern Europe experienced greater changes across health metrics compared to Central Europe, with higher average annual percentage change values for incidence, prevalence, mortality, and DALYs rates. In 2021, Lithuania and Estonia recorded the highest PCa prevalence rates, while Estonia had the highest total percentage change (240.3). Estonia and Latvia also had the highest mortality rates (34.1 and 33.6 per 100,000, respectively). CEE’s prevalence rates are projected to remain stable. Conclusion: The findings highlight significant regional disparities in the burden of prostate cancer in CEE. Efforts to address these disparities should focus on enhancing diagnostic programs and treatment access, particularly in Eastern Europe, to reduce the ongoing burden of PCa in the region. © 2025 Informa UK Limited, trading as Taylor & Francis Group.
University Center for Research and Development, Chandigarh University, Mohali, India; Faculty of Data Science and Information Technology, INTI International University, Nilai, Malaysia; One Health Centre (COHERD), Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education, Wardha, India; Department of Microbiology, Faculty of Science, Marwadi University Research Center, Rajkot, India; Department of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, India; Department of Pharmacology, IMS and SUM Hospital, Siksha ‘O’ Anusandhan (Deemed to be University), Odisha, Bhubaneswar, India; Department of Biomedical Sciences, Sathyabama Institute of Science and Technology, Chennai, India; Chitkara Centre for Research and Development, Chitkara University Institute of Engineering and Technology, Chitkara University, India; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India; Department of Biotechnology, Graphic Era (Deemed to be University), Clement Town, Dehradun, India; Graphic Era Hill University, Clement Town, Dehradun, India; Department of Paediatrics, Dr.D. Y. Patil Medical College Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed-to-be-University), Pune, Pimpri, India; Department of Public Health Dentistry, Dr. D. Y. Patil Medical College Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed-to-be-University), Pune, Pimpri, India; Department of Medicine, Korea Universtiy, Seoul, South Korea; Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India; Medical Laboratories Techniques Department, AL-Mustaqbal University, Babil, Hillah, Iraq; Faculty of Mathematics and Natural Sciences, Universitas Negeri Padang, Padang, Indonesia; Centre for Research Impact and Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, India; Division of Research and Innovation, Uttaranchal University, Dehradun, India
